Doximity (DOCS) stock ripped higher on Aug. 7 after the online networking service for medical professionals recorded a market-beating Q1 and raised its guidance for the full year. The company posted a 7% year-on-year increase in revenue to $156.6 million, on $0.29 in earnings per share (EPS), a cent above the consensus estimate.
Doximity shares have reversed a major chunk of their post-earnings gains in recent hours, but they remain up about 50% versus their year-to-date low in mid-May.
Doximity Cites AI for Quarterly Strength
In the earnings release, DOCS management said enterprise expansion helped reaccelerate growth in the core business, with net revenue retention coming in at 112% for the top 20 clients.
Doximity now boasts 127 enterprise customers, generating more than $500,000 in annual recurring revenue.
Beyond topline growth, the firm’s adjusted EBITDA also reached $75 million, representing a solid 48% margin — strength it attributed to rapid adoption of its AI-powered workflow and search tools.
These new offerings are deepening physician engagement while strengthening the company’s competitive moat across health systems and pharmaceutical clients.
Is It Too Late to Invest in DOCS Shares?
Management’s full-year outlook suggests there’s still time to build a position in Doximity stock at an attractive valuation.
On Friday, the company raised its 2027 sales guidance by $6 million, indicating it expects the Q1 momentum to sustain through the remainder of its current financial year.
DOCS’s improving financial profile, combining expanding subscription revenues with near 50% EBITDA margins, makes it a compelling buy at about a 40% discount to its year-to-date high.
Plus, early traction in its proprietary clinical AI suite opens up a substantial long-term monetization runway as well.
Note that Doximity broke above its major moving averages (MAs) today, reinforcing that bulls have taken back control across multiple timeframes.
Wall Street’s View on Doximity
Heading into the Q1 release, Wall Street had a consensus “Moderate Buy” rating on DOCS shares, with a mean price target of about $24.50.
However, it’s well within reason to expect some upward revisions as analysts move to factor in the company’s strong Q1 and raise future guidance in the days ahead.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/Netflix%20open%20on%20tablet%20by%20rswebsols%20via%20Pixabay.jpg)